News
Drug and biotech news
Last checked: Nov 19, 2026Source: BioPharma Dive, STAT (pharma), FDA press releases, FDA MedWatch, Drugs@FDA (new approvals), openFDA (Class I recalls)
23 stories
- FDAFDA MedWatchNov 19, 2026Early Alert: Outset Medical Updates Use Instructions for the Tablo Console and the TabloCart with Prefiltration Drawer
Outset Medical Tablo Console and TabloCart with Prefiltration Drawer power cord connections may overheat, posing fire, burn, and treatment interruption risks.
- FDAFDA press releasesNov 18, 2026FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).
- FDAFDA press releasesNov 17, 2026FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide
FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health...
- FDAFDA press releasesNov 17, 2026FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
- FDAFDA MedWatchNov 12, 2026Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen
FOR IMMEDIATE RELEASE – November 12, 2026 - Tampa, Florida. Game Changer Products LLC is voluntarily recalling all lots of 10 Day Forecast capsules to the consumer level. FDA analysis has found the product to be tainted...
- FDAFDA press releasesNov 9, 2026FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate...
- FDAFDA MedWatchNov 9, 2026Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter
FOR IMMEDIATE RELEASE –November 06,2026 – East Windsor, New Jersey, Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL...
- FDAFDA MedWatchNov 6, 2026MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy: FDA Safety Communication
- FDAFDA press releasesNov 5, 2026FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell...
- FDAFDA press releasesNov 2, 2026FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality
The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products...
- FDAFDA press releasesOct 30, 2026FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).
- FDAFDA MedWatchOct 21, 2026Wedgewood Pharmacy Issues Recall of Certain Compounded Veterinary Medications Within Expiry Due to Potential Potency Issues
SWEDESBORO, N.J., (October 21, 2026) - Wedgewood Pharmacy LLC ("Wedgewood") is recalling certain compounded veterinary medications within expiry at the provider/customer level due to inconsistencies in the reliability...
- FDAFDA press releasesOct 20, 2026FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment
FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.
- FDAFDA press releasesOct 20, 2026FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women
Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an...
- FDAFDA press releasesOct 20, 2026FDA Issues Final Guidance on Prescription Drug Apps and Software
The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.
- FDAFDA press releasesOct 19, 2026FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common...
- FDAFDA press releasesOct 14, 2026FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development
The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics...
- FDAFDA press releasesOct 14, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
- FDAFDA press releasesOct 5, 2026FDA Seeks Public Input to Support Ibogaine Research
The U.S. Food and Drug Administration today announced a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking...
- FDAFDA press releasesOct 1, 2026FDA Approves First Heart Valve Designed to Grow with Children
The U.S. Food and Drug Administration today approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.
- FDAFDA press releasesSep 30, 2026FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees
The U.S. Food and Drug Administration today announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees— the independent bodies that inform some...
- FDAFDA press releasesSep 29, 2026FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme
The U.S. Attorney’s Office for the Middle District of Florida and the Criminal Division of the U.S. Department of Justice today announced federal charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian...
- FDAFDA press releasesSep 28, 2026FDA Approves First Treatment for MCT8 Deficiency
The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid...
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.